



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

ANDA 75-804

Food and Drug Administration
Rockville MD 20857

SEP 25 2002

Barr Laboratories, Inc.
Attention: Nicholas C. Tantillo
2 Quaker Road
P.O. Box 2900
Pomona, NY 10970

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated February 16, 2000, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Sprintec™-28 Tablets (Norgestimate and Ethinyl Estradiol Tablets, 0.25 mg/0.035 mg, respectively), packaged in a 28-day cycle regimen.

Reference is also made to your amendments dated April 10, May 2, and November 28, 2000; February 1, April 20, and October 12, 2001; and July 9, September 4, September 5, and September 10, 2002.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the application is approved. The Division of Bioequivalence has determined your Sprintec™-28 Tablets to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Ortho-Cyclen®-28 Tablets, of RW Johnson Pharmaceutical Research Institute). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.


Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy that you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FDA 2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,



Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research